Sofinnova Partners has closed a new €82 million fund dedicated to backing its medtech portfolio companies through to Series B, extending its ability to support startups beyond the earliest stages. The move strengthens the firm’s long-standing focus on life sciences and medical technologies, giving it additional capital to continue financing companies as they move from initial development toward clinical and commercial validation.
The fund is designed to follow existing investments rather than spread broadly across the market, allowing Sofinnova to reinforce its position in companies already identified as promising. By reserving capital for later rounds, the firm can help its medtech startups bridge the gap between seed and Series B, a phase that is often difficult to finance in Europe.
The closing of this vehicle reflects continued investor interest in healthcare innovation and in specialized funds with deep sector expertise. For Sofinnova, the €82 million raise provides more room to accompany portfolio companies through the more capital-intensive stages of growth, where product development, regulatory work and market entry typically require larger checks and longer support.